UNPRI

EQS-News: Golding Capital Partners GmbH: Golding study: funds of funds reduce volatility in private markets by 90 per cent

Retrieved on: 
Wednesday, November 30, 2022

The significant advantage of up to 90 per cent for risk diversification by means of funds of funds is confirmed for the buyout asset class and fundamentally also for infrastructure and private credit.

Key Points: 
  • The significant advantage of up to 90 per cent for risk diversification by means of funds of funds is confirmed for the buyout asset class and fundamentally also for infrastructure and private credit.
  • By exactly how much do funds of funds reduce investors risk of loss, especially in private markets?
  • And indeed, in all three cases we can definitely recommend the vast majority of investors to diversify via funds of funds.
  • By contrast, the worst five per cent of funds of funds still generated a positive multiple of up to 1.15.

EQS-News: Golding Capital Partners GmbH: Golding raises €75 million at the first closing of its début private debt co-investment fund

Retrieved on: 
Sunday, November 27, 2022

Munich, 15th November 2022 Golding Capital Partners has received capital commitments of 75 million at the first closing of its inaugural dedicated co-investment fund in the private credit asset class.

Key Points: 
  • Munich, 15th November 2022 Golding Capital Partners has received capital commitments of 75 million at the first closing of its inaugural dedicated co-investment fund in the private credit asset class.
  • Experienced existing investors seized the opportunity offered by the initial fundraising phase to subscribe for Golding Private Debt Co-Investment 2021, which has a target volume of 200 million.
  • Golding Private Debt Co-Investment 2021 gives institutional investors access to the breadth of the European direct lending market.
  • The fund Golding Private Debt Co-Investment 2021 is structured as a Luxembourg SCS SICAV-FIAR and has a lifetime of eight years.

SEMCAP Announces First Annual Impact Report and Adoption of Formal ESG Framework

Retrieved on: 
Tuesday, November 15, 2022

As seasoned investors, weve spent many years investing in and building companies that transform industries and change the way business is conducted.

Key Points: 
  • As seasoned investors, weve spent many years investing in and building companies that transform industries and change the way business is conducted.
  • In launching SEMCAP, we resolved to expand on those efforts to build valuable companies with the greatest potential impact on humanity and the environment, said Walter Buck Buckley, co-founder and co-CIO at SEMCAP.
  • SEMCAP will continue to challenge its team and portfolio companies across its three verticals to lead the change needed.
  • Importantly, SEMCAP is also committed to ensuring the firms internal practices and culture align with its social and environmental values.

Golding Raises €75 Million at the First Closing of its Début Private Debt Co-investment Fund

Retrieved on: 
Tuesday, November 15, 2022

Golding Capital Partners has received capital commitments of 75 million at the first closing of its inaugural dedicated co-investment fund in the private credit asset class.

Key Points: 
  • Golding Capital Partners has received capital commitments of 75 million at the first closing of its inaugural dedicated co-investment fund in the private credit asset class.
  • Experienced existing investors seized the opportunity offered by the initial fundraising phase to subscribe for Golding Private Debt Co-Investment 2021, which has a target volume of 200 million.
  • Golding Private Debt Co-Investment 2021 gives institutional investors access to the breadth of the European direct lending market.
  • The fund Golding Private Debt Co-Investment 2021 is structured as a Luxembourg SCS SICAV-FIAR and has a lifetime of eight years.

Legend Capital Portfolio Company Atour Successfully Lists on Nasdaq

Retrieved on: 
Sunday, November 13, 2022

HONG KONG, Nov 13, 2022 - (ACN Newswire) - On the evening of November 11, Beijing time, Legend Capital portfolio company Atour Lifestyle Holdings Limited ("Atour") was officially listed on the Nasdaq Stock Exchange in the United States.

Key Points: 
  • HONG KONG, Nov 13, 2022 - (ACN Newswire) - On the evening of November 11, Beijing time, Legend Capital portfolio company Atour Lifestyle Holdings Limited ("Atour") was officially listed on the Nasdaq Stock Exchange in the United States.
  • Founded in 2013, Atour is a leading hospitality and lifestyle company in China with a distinct portfolio of lifestyle hotel brands, such as A.T. HOUSE, Atour S, ZHOTEL, Atour Hotel, Atour X and Atour Light, as well as scenario-based retail brands, including Atour Market.
  • As an important institutional investor and close partner of Atour, Legend Capital led the investment in Atour in 2016, and continued to make additional investments in Atour's subsequent financing rounds in 2017 and 2021.
  • Legend Capital said: " The past nine years have witnessed Atour's continuous development since its first hotel opening in 2013.

Led by Legend Capital, PureFDA Secures Over CNY100 million in the Series B Round

Retrieved on: 
Thursday, November 10, 2022

HONG KONG, Nov 10, 2022 - (ACN Newswire) - Recently, PureFDA Medical Technology (Guangzhou) Co., LTD. (hereinafter referred to as "PureFDA") announced the completion of the Series B round of financing of over CNY100 million, which was led by Legend Capital and followed by the existing shareholder Bayland Capital.

Key Points: 
  • HONG KONG, Nov 10, 2022 - (ACN Newswire) - Recently, PureFDA Medical Technology (Guangzhou) Co., LTD. (hereinafter referred to as "PureFDA") announced the completion of the Series B round of financing of over CNY100 million, which was led by Legend Capital and followed by the existing shareholder Bayland Capital.
  • The company's service network has spread to 10 countries and regions worldwide, including the United States, Germany, Italy, Spain, Switzerland and Poland.
  • Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add.
  • As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative.

Legend Capital Portfolio Company Giant Biogene Successfully Lists on the HKEX

Retrieved on: 
Monday, November 7, 2022

HONG KONG, Nov 7, 2022 - (ACN Newswire) - On November 4, 2022, Legend Capital portfolio company Giant Biogene (2367.HK) was successfully listed on the main board of the Hong Kong Stock Exchange.

Key Points: 
  • HONG KONG, Nov 7, 2022 - (ACN Newswire) - On November 4, 2022, Legend Capital portfolio company Giant Biogene (2367.HK) was successfully listed on the main board of the Hong Kong Stock Exchange.
  • Richard LI, President of Legend Capital, said: "Congratulations to Giant Biogene on its successful listing on the main board of the Hong Kong Stock Exchange.
  • Legend Capital is very honored to be an investor in Giant Biogene and to carry out in-depth investment cooperation with the company.
  • Tony WANG, Managing Director of Legend Capital, said: "Giant Biogene is a pioneer in the synthetic biology industry.

Nasdaq’s Net-Zero Target Approved by The Science Based Targets initiative

Retrieved on: 
Thursday, November 3, 2022

NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) announced today that its near- and long-term science-based emissions reduction targets have been approved by The Science Based Targets initiative (SBTi). Nasdaq has pledged to reduce absolute Scope 1 and Scope 2 greenhouse gas (GHG) emissions 100% and absolute Scope 3 GHG emissions 50% by 2030. SBTi has also validated Nasdaq’s pledge to reduce Scope 3 GHG emissions 95% to reach net-zero by 2050.

Key Points: 
  • NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) announced today that its near- and long-term science-based emissions reduction targets have been approved by The Science Based Targets initiative (SBTi).
  • SBTi has also validated Nasdaqs pledge to reduce Scope 3 GHG emissions 95% to reach net-zero by 2050.
  • Ensure that 70% of its suppliers by spend, covering purchased goods and services and capital goods, will set science-based targets by 2027.
  • About Science Based Targets initiative:
    The Science Based Targets initiative (SBTi) is a global body enabling businesses to set ambitious emissions reductions targets in line with the latest climate science.

Led by Legend Capital, ClinBrain Completes Nearly CNY200 million Series C Round

Retrieved on: 
Tuesday, November 1, 2022

HONG KONG, Nov 1, 2022 - (ACN Newswire) - Recently, the healthcare big data leader ClinBrain completed the Series C round of financing of nearly CNY200 million, led by Legend Capital.

Key Points: 
  • HONG KONG, Nov 1, 2022 - (ACN Newswire) - Recently, the healthcare big data leader ClinBrain completed the Series C round of financing of nearly CNY200 million, led by Legend Capital.
  • ClinBrain has been committed to the direction of data governance and intelligent application of hospitals.
  • Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add.
  • As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative.

Led by Legend Capital, Easy-Flow Raises Tens of Millions of CNY in Angel Round

Retrieved on: 
Tuesday, November 1, 2022

HONG KONG, Nov 1, 2022 - (ACN Newswire) - Shanghai Easy-Flow ("Easy-Flow") recently completed its Angel financing round by raising tens of millions of CNY, led by Legend Capital.

Key Points: 
  • HONG KONG, Nov 1, 2022 - (ACN Newswire) - Shanghai Easy-Flow ("Easy-Flow") recently completed its Angel financing round by raising tens of millions of CNY, led by Legend Capital.
  • Founded in November 2021, Easy-Flow is committed to efficiently creating a complete set of solutions in the field of peripheral interventional devices.
  • The company develops products such as drug balloons, catheters, stents, and thrombus removal equipment for treating peripheral arteriovenous diseases.
  • Regarding this financing round, Joe ZHOU, managing director of Legend Capital, said: " Legend Capital has long focused on investment in medical devices.